Post by
Noteable on Mar 07, 2023 4:58pm
US$10 Billion is a typical estimate for a M&A in 2023
"Les Funtleyder, a healthcare portfolio manager at E Squared Capital Management, said he expected Pfizer would make a series of acquisitions this year. These would likely focus on companies that are typically $10bn or below with products close to being commercialised, he said."
https://www.ft.com/content/ba2cba41-0a13-4251-bbd7-2abeff90433f
Comment by
Noteable on Oct 29, 2023 6:54pm
As KPMG reported in its Biopharm Deal Trends Outlook for 2023, and continues to still apply, “ Currently there is a dearth of available quality mid and late-stage assets in oncology “ . https://kpmg.com/kpmg-us/content/dam/kpmg/pdf/2023/biopharma-deal-trends-outlook.pdf